/ Not yet recruitingNot Applicable An open label, balanced, randomized, two-treatment, two-sequence, two-period, single oral dose, crossover, bioequivalence study on Bilastine 20 mg and Montelukast 10 mg tablet of Rivpra Formulation Pvt. ltd., in comparison with BILAFAV M Tablet (Bilastine 20 mg and Montelukast 10 mg) of Hetero Labs Ltd in healthy, adult, human subjects under fasting conditions.
/ CompletedNot Applicable An open label, balanced, randomized, two-treatment, two-sequence, two-period, single oral dose, crossover, bioequivalence study on Bilastine 10 mg and Montelukast 4 mg per 5ml oral suspension of Rivpra Formulation Pvt. ltd., in comparison with Bilafav-M Suspension 10mg/4mg per 5 ml (Bilastine 10 mg and Montelukast 4 mg) of Synokem Pharmaceuticals Ltd., in healthy, adult, human subjects under fasting conditions. - NIl
100 Clinical Results associated with Rivpra Formulation Pvt Ltd.
0 Patents (Medical) associated with Rivpra Formulation Pvt Ltd.
100 Deals associated with Rivpra Formulation Pvt Ltd.
100 Translational Medicine associated with Rivpra Formulation Pvt Ltd.